Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CONTEXT: The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently undergone scrutiny. OBJECTIVE: The objective of the study was to characterize the risk of adverse events associated with glucose-lowering therapies in people with T2DM. DESIGN AND SETTING: This was a retrospective cohort study using data from the UK General Practice Research Database, 2000-2010. PATIENTS: Patients comprised 84 622 primary care patients with T2DM treated with one of five glucose-lowering regimens: metformin monotherapy, sulfonylurea monotherapy, insulin monotherapy, metformin plus sulfonylurea combination therapy, and insulin plus metformin combination therapy. There were 105 123 exposure periods. MAIN OUTCOME MEASURES: The risk of the first major adverse cardiac event, first cancer, or mortality was measured. Secondary outcomes included these individual constituents and microvascular complications. RESULTS: In the same model, and using metformin monotherapy as the referent, the adjusted hazard ratio (aHR) for the primary end point was significantly increased for sulfonylurea monotherapy (1.436, 95% confidence interval [CI] 1.354-1.523), insulin monotherapy (1.808, 95% CI 1.630-2.005), and insulin plus metformin (1.309, 95% CI 1.150-1.491). In glycosylated hemoglobin/morbidity subgroups, patients treated with insulin monotherapy had aHRs for the primary outcome ranging from 1.469 (95% CI 0.978-2.206) to 2.644 (95% CI 1.896-3.687). For all secondary outcomes, insulin monotherapy had increased aHRs: myocardial infarction (1.954, 95% CI 1.479-2.583), major adverse cardiac events (1.736, 95% CI 1.441-2.092), stroke (1.432, 95% CI 1.159-1.771), renal complications (3.504, 95% CI 2.718-4.518), neuropathy (2.146, 95% CI 1.832-2.514), eye complications (1.171, 95% CI 1.057-1.298), cancer (1.437, 95% CI 1.234-1.674), or all-cause mortality (2.197, 95% CI 1.983-2.434). When compared directly, aHRs were higher for insulin monotherapy vs all other regimens for the primary end point and all-cause mortality. CONCLUSIONS: In people with T2DM, exogenous insulin therapy was associated with an increased risk of diabetes-related complications, cancer, and all-cause mortality. Differences in baseline characteristics between treatment groups should be considered when interpreting these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin therapy has raised similar concerns with respect to cardiovascular safety and has been associated with adverse cardiovascular outcomes and mortality in observational studies.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125 · cited 8×
“670 Currie et al Clinical Outcomes of Treatment With Insulin J Clin Endocrinol Metab, February 2013, 98(2):668–677”
InfluentialThe National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“3 mmol/L with insulin glargine vs usual care over an estimated five-year treatment period in people with established cardiovascular disease coupled with glucose intolerance or early T2DM (29).”
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 2×
“Indeed, endogenous hyperinsulinemia has been linked to an increase in cancer incidence in people without diabetes (30), whereas epidemiological data have linked exogenous insulin therapy with an increased cancer incidence in people with T2DM (22).”
BackgroundSelf-citationGerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Ford, E., Carroll, J. A., Smith, H. E., Scott, D., & Cassell, J. A. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv180 · Cited by 408
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Identification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238
Insulin: too much of a good thing is bad
Kolb, H., Kempf, K., Röhling, M., & Martin, S. (2020) · BMC Medicine · doi:10.1186/s12916-020-01688-6 · Cited by 237
Clinical inertia to insulin initiation and intensification in the UK: A focused literature review
Khunti, K., & Millar-Jones, D. (2017) · Primary Care Diabetes · doi:10.1016/j.pcd.2016.09.003 · Cited by 235
Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015) · Diabetes · doi:10.2337/db14-0694 · Cited by 226
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 220
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundKhunti, K., Knighton, P., Zaccardi, F., Bakhai, C., Barron, E., Holman, N., Kar, P., Meace, C., Sattar, N., Sharp, S., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00050-4 · Cited by 192
Zare, R., Nadjarzadeh, A., Zarshenas, M. M., Shams, M., & Heydari, M. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.03.003 · Cited by 188
Diabetes Burden and Diabetes Distress: the Buffering Effect of Social Support
Baek, R. N., Tanenbaum, M. L., & Gonzalez, J. S. (2014) · Annals of Behavioral Medicine · doi:10.1007/s12160-013-9585-4 · Cited by 181
Roumie, C. L., Greevy, R. A., Grijalva, C. G., Hung, A. M., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2014) · JAMA · doi:10.1001/jama.2014.4312 · Cited by 173
Koye, D. N., Shaw, J. E., Reid, C. M., Atkins, R. C., Reutens, A. T., & Magliano, D. J. (2017) · Diabetic Medicine · doi:10.1111/dme.13324 · Cited by 140
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
Herman, M. E., O’Keefe, J. H., Bell, D. S. H., & Schwartz, S. S. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.09.001 · Cited by 130
Zhang, Z.-J., Bi, Y., Li, S., Zhang, Q., Zhao, G., Guo, Y., & Song, Q. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu124 · Cited by 120
Ma, J., Yu, H., Liu, J., Chen, Y., Wang, Q., & Xiang, L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.010 · Cited by 124
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
The Coming Age of Flavonoids in the Treatment of Diabetic Complications
Caro-Ordieres, T., Marín-Royo, G., Opazo-Ríos, L., Jiménez-Castilla, L., Moreno, J. A., Gómez-Guerrero, C., & Egido, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020346 · Cited by 107
Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients
Sciacca, L., Vigneri, R., Tumminia, A., Frasca, F., Squatrito, S., Frittitta, L., & Vigneri, P. G. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.006 · Cited by 118
Diabetes and Cancer—An AACE/ACE Consensus Statement
Handelsman, Y., LeRoith, D., Bloomgarden, Z. T., Dagogo-Jack, S. E., EINHORN, D. F., Garber, A. J., Grunberger, G., Harrell, R. M., Gagel, R. F., Lebovitz, H. E., et al. (2013) · Endocrine Practice · doi:10.4158/ep13248.cs · Cited by 105
Nyström, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 84
Rethinking the Relationship between Insulin and Cancer
Vigneri, R., Sciacca, L., & Vigneri, P. G. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.05.004 · Cited by 96
Norhammar, A., Bodegård, J., Nyström, T., Thuresson, M., Nathanson, D., & Eriksson, J. W. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13627 · Cited by 83
The Growing Prevalence of Type 2 Diabetes: Increased Incidence or Improved Survival?
Maruthur, N. M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0426-4 · Cited by 95
Zhang, K., Yang, W., Dai, H., & Deng, Z. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108001 · Cited by 86
Diabetes and Breast Cancer Subtypes
Bronsveld, H. K., Jensen, V., Vahl, P., Bruin, M. L. D., Cornelissen, S., Sanders, J., Auvinen, A. P., Haukka, J. K., Andersen, M. T., Vestergaard, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170084 · Cited by 79
Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Schernthaner, G.-H., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12412 · Cited by 78
Self-citationRecent HbA1c Values and Mortality Risk in Type 2 Diabetes. Population-Based Case-Control Study
Nicholas, J., Charlton, J., Dregan, A., & Gulliford, M. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068008 · Cited by 66
Experiences of diabetes self‐management: a focus group study among A ustralians with type 2 diabetes
Carolan, M. C., Holman, J., & Ferrari, M. (2014) · Journal of Clinical Nursing · doi:10.1111/jocn.12724 · Cited by 114
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
Irons, B. K., & Minze, M. G. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38753 · Cited by 76
Cardiovascular impact of drugs used in the treatment of diabetes
Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 67
Zhong, V. W., Juhaeri, J., Cole, S. R., Kontopantelis, E., Shay, C. M., Gordon-Larsen, P., & Mayer-Davis, E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2680 · Cited by 62
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Bronsveld, H. K., ter Braak, B., Karlstad, Ø., Vestergaard, P., Starup‐Linde, J., Bazelier, M. T., Bruin, M. L. D., de Boer, A., Siezen, C. L. E., van de Water, B., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0611-2 · Cited by 57
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 62
Bannister, C. A., Poole, C., Jenkins‐Jones, S., Morgan, C. L., Elwyn, G. J., Spasić, ., & Currie, C. J. (2013) · Diabetes Care · doi:10.2337/dc13-1159 · Cited by 53
Self-citationMetformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation
Farmer, R. E., Ford, D., Forbes, H. J., Chaturvedi, N., Kaplan, R. S., Smeeth, L. L., & Bhaskaran, K. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw275 · Cited by 60
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.003 · Cited by 63
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.004 · Cited by 52
Sulfonylurea derivatives and cancer, friend or foe?
Hendriks, A. M., Schrijnders, D., Kleefstra, N., de Vries, E. G. E., Bilo, H. J. G., Jalving, M., & Landman, G. W. D. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172598 · Cited by 54
Khan, S. Z., Rivero, M., Nader, N. D., Cherr, G. S., Harris, L. M., Dryjski, M. L., & Dosluoglu, H. H. (2018) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2018.05.054 · Cited by 47
Xiang, L., Zhang, H., Wei, J., Tian, X. Y., Luan, H., Li, S., Zhao, H., Cao, G., Chung, A. C. K., Yang, C., et al. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.11.082 · Cited by 43
Determinants of mortality in patients with type 2 diabetes: a review
Engelmann, J., Manuwald, U., Rubach, C., Kügler, J., Birkenfeld, A. L., Hanefeld, M., & Rothe, U. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9349-0 · Cited by 44
Zhuang, X., He, X., Yang, D.-Y. D., Guo, Y., He, J., Xiao, H., & Liao, X. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0722-z · Cited by 43
Tuccori, M., Wu, J. W., Yin, H., Majdan, A., & Azoulay, L. (2015) · Diabetes Care · doi:10.2337/dc15-1358 · Cited by 39
Brown, A., Dornhorst, A., McGowan, B., Omar, O., Leeds, A. R., Taheri, S., & Frost, G. S. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001012 · Cited by 38
Chen, Y., Du, L., Li, L., Ma, J., Geng, X., Yao, X., Liu, G., & Sun, X. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12435 · Cited by 37
Intensive insulin for type 2 diabetes: the risk of causing harm
Nolan, C. J., Ruderman, N. B., & Prentki, M. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70027-5 · Cited by 37
Russell, J. S., Toit, E. F. D., Peart, J. N., Patel, H. H., & Headrick, J. P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0638-z · Cited by 38
Anyanwagu, U., Mamza, J., Mehta, R., Donnelly, R., & Idris, I. (2016) · Heart · doi:10.1136/heartjnl-2015-309164 · Cited by 34
Safety of antidiabetes medications: An update
Bailey, C. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.125 · Cited by 33
Zinman, B., Åhrén, B., Neubacher, D., Patel, S. D., Woerle, H., & Johansen, O. E. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.06.010 · Cited by 34
Palliative and end of life care of people with diabetes: issues, challenges and strategies
Dunning, T., & Martin, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.018 · Cited by 32
Holden, S. E., Jenkins‐Jones, S., & Currie, C. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153594 · Cited by 34
Self-citationMortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study
Claesen, M., Gillard, P., Smet, F. D., Callens, M., Moor, B. D., & Mathieu, C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3184 · Cited by 32
Mekuria, A. N., Ayele, Y., Tola, A., & Mishore, K. M. (2019) · Journal of Diabetes Research · doi:10.1155/2019/7676909 · Cited by 29
Lazo, M., Bernabé‐Ortiz, A., Pinto, M. E., Ticse, R., Málaga, G., Sacksteder, K. A., Miranda, J. J., & Gilman, R. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095403 · Cited by 36
Drug–subphenotype interactions for cancer in type 2 diabetes mellitus
Yang, X., Lee, H. M., & Chan, J. C. N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.37 · Cited by 28
Nogueira, K. C., Furtado, M., Fukui, R. T., Correia, M. R. S., dos Santos, R. F., Andrade, J. L., & da Silva, M. E. R. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-103 · Cited by 29
Haddad, M. E., Eid, S., Harb, F., Massry, M. E., Azar, S. T., Sauleau, E., & Eid, A. A. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.02.011 · Cited by 30
Fransgaard, T., Thygesen, L. C., & Gögenür, I. (2018) · International Journal of Cancer · doi:10.1002/ijc.31305 · Cited by 25
Ma, J., Liu, J., Yu, H., Chen, Y., Wang, Q., & Xiang, L. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1803-y · Cited by 25
Divergent Effects of Various Diabetes Drugs on Cardiovascular Prognosis
Bell, D. S. H., Patil, H., & O’Keefe, J. H. (2013) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0671 · Cited by 27
Price, H. I., Agnew, M. D., & Gamble, J. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006341 · Cited by 25
Antidiabetic treatment, stroke severity and outcome
Magkou, D., & Τζιόμαλος, Κ. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.84 · Cited by 24
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Wysham, C., Campos, C., & Kruger, D. F. (2018) · Clinical Diabetes · doi:10.2337/cd17-0064 · Cited by 24
Arundel, C., Sheriff, H. M., Bearden, D. M., Morgan, C. J., Heidenreich, P. A., Fonarow, G. C., Butler, J., Allman, R. M., & Ahmed, A. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.77562 · Cited by 24
Self-citationBasal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Monnier, L., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.003 · Cited by 24
Li, J., Tong, Y., Zhang, Y., Tang, L., Lv, Q., Zhang, F., Hu, R., & Tong, N. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.006 · Cited by 27
Alkharaiji, M. A., Anyanwagu, U., Donnelly, R., & IDRIS, I. R. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03809-4 · Cited by 22
Mortality risk with sulphonylureas compared to metformin
Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12280 · Cited by 23
Self-citationAnyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.003 · Cited by 21
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.002 · Cited by 23
Impact of type 2 diabetes mellitus on recurrent myocardial infarction in China
Li, W., Li, M., Gao, C., Wang, X., Qi, D., Liu, J., & Jin, Q. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116653606 · Cited by 23
A review of mortality in type 2 diabetes mellitus
Asfandiyarova, N. S. (2015) · Diabetes Mellitus · doi:10.14341/dm6846 · Cited by 21
Mendez, C. E., Walker, R. J., Eiler, C., Mishriky, B. M., & Egede, L. E. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1643635 · Cited by 22
Anyanwagu, U., Donnelly, R., & IDRIS, I. R. (2019) · American Journal of Nephrology · doi:10.1159/000496276 · Cited by 18
Diabetes mellitus associated neurovascular lesions in the retina and brain: A review
Sinclair, S. H., Miller, E. S., Talekar, K. S., & Schwartz, S. S. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1012804 · Cited by 22
Datta‐Nemdharry, P., Thomson, A., Beynon, J., & Donegan, K. L. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4092 · Cited by 18
Lysy, Z., Fung, K., Giannakeas, V., Fischer, H. D., Bell, C. M., & Lipscombe, L. L. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-04849-3 · Cited by 19
Zghebi, S. S., Steinke, D. T., Rutter, M. K., Emsley, R., & Ashcroft, D. M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12692 · Cited by 21
Kung, F.-P., Tsai, C.-F., Lu, C., Huang, L.-C., & Lu, C. (2020) · Medicine · doi:10.1097/md.0000000000019139 · Cited by 18
Lawrence, W. R., Hosler, A. S., Gates, M. A., Leinung, M. C., Zhang, X., Schymura, M. J., & Boscoe, F. P. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101710 · Cited by 20
Lee, Y., Han, K., Kim, B., Choi, M. S., Park, J., Kim, M., Jin, S., Hur, K. Y., Kim, G., & Kim, J. H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13539 · Cited by 20
Haltmeier, T., Benjamin, E., Beale, E., Inaba, K., & Δημητριάδης, Δ. (2016) · World Journal of Surgery · doi:10.1007/s00268-016-3469-2 · Cited by 20
Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
Suissa, S. (2018) · Diabetes Care · doi:10.2337/dc17-1059 · Cited by 16
Mamza, J., Rajnikant, M., Donnelly, R., & IDRIS, I. R. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116687102 · Cited by 17
Abualsuod, A. M., Rutland, J. J., Watts, T. E., Pandat, S. S., Delongchamp, R. R., & Mehta, J. L. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6601-x · Cited by 15
Grewal, S., Zaman, N., Borgatta, L., Nudy, M., Foy, A. J., & Peterson, B. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.05.043 · Cited by 14
Reducing the Burden of Mortality in Older People With Diabetes: A Review of Current Research
Forbes, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00133 · Cited by 20
Bell, D. S. H., & Gonçalves, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108199 · Cited by 14
Cardiovascular effects of basal insulins
Mannucci, E., Giannini, S., & Dicembrini, I. (2015) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s43300 · Cited by 15
Siddiqi, L., Aarsen, K. V., Iansavitchene, A., & Yan, J. W. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.11.008 · Cited by 13
Metadata
- Authors
- Currie, C. J., Poole, C. D., Evans, M., Peters, J. R., & Morgan, C. L.
- Affiliations
- Cardiff University (GB)
- University Hospital of Wales (GB)
- Corresponding author
- Currie, Craig J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-02-01
- Volume
- 98
- Issue
- 2
- Pages
- 668-677
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3612791
- OpenAlex
- W2157836715
- Cited by
- 203
- References
- 38
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 7 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 25 · 2017: 18 · 2016: 26 · 2015: 23 · 2014: 19 · 2013: 12
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin monotherapy, metformin, major adverse cardiac events, myocardial infarction, stroke, cancer risk, mortality, microvascular complications, renal complications, HbA1c, adverse drug reactions, primary care patients
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Prognosis, Retrospective Studies, Risk, Sulfonylurea Compounds, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.